Doctor of Osteopathy Program year 2021 Source: CMS Open Payments, 2026 publication

Mark Walker

Rio Rancho, NM Doctor of Osteopathy

CMS profile 11303870

2240 Grande Blvd Se, Rio Rancho, NM 87124

Open in the dashboard

General payments

$20,524

70 records reported · program year 2021

Research payments

$0

Paid to them · None reported · program year 2021

Ownership & investment interest

$0

None reported

Through program year 2021, Mark Walker of Rio Rancho, NM is reported in the CMS Open Payments database as having received $20,524 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2021 General $20,524 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Walker
  • New Mexico median
  • Middle half of New Mexico
  • National median

In program year 2025, general payments to Mark Walker were reported at $0. Among 4,895 New Mexico profiles paid that year, the median was $135 and the middle half received between $43 and $454.

Show as a table
Year Mark Walker New Mexico median Middle half National median
2019 $0 $125 $40–$475 $163
2020 $0 $82 $26–$244 $114
2021 $20,524 $102 $28–$300 $132
2022 $0 $123 $37–$363 $149
2023 $0 $129 $36–$413 $160
2024 $0 $133 $39–$419 $164
2025 $0 $135 $43–$454 $169

Breakdown

Who paid General payments · program year 2021
  1. Novo Nordisk Inc $20,524 70 payments

Every payment, record by record

What the payments were for General payments · program year 2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,051 7 payments
  2. Consulting Fee $3,570 2 payments
  3. Travel and Lodging $1,657 4 payments
  4. Food and Beverage $1,053 51 payments
  5. Education $194 6 payments
Products named General payments · program year 2021
  1. Wegovy $10,137 24 payments
  2. Saxenda $9,853 20 payments
  3. RYBELSUS $340 20 payments
  4. Ozempic $229 19 payments
  5. Tresiba $45 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record